Centrient Pharmaceuticals has signed an agreement for the acquisition of Astral SteriTech Private Limited, an international manufacturer specialized in sterile antibiotic injectable finished dosage forms. With the acquisition of Astral SteriTech, Centrient strengthens its position in beta-lactam antibiotics.
 
The products offered by Astral SteriTech are sterile injectable finished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins. Being close to Centrient’s core products of beta-lactam antibiotics, the acquired product portfolio provides Centrient a diversification opportunity within the growing niche segment of sterile injectable antibiotics.
 
With the broadened product portfolio, Centrient can further meet the needs of its customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms.
 
Astral SteriTech has a U.S. FDA-approved manufacturing site with two manufacturing lines and serves customers in highly regulated markets like the U.S. and other regions such as South Asia.
 
The transaction is subject to customary regulatory approvals and closing conditions.
 
“The acquisition of Astral SteriTech is a significant step forward on the journey we at Centrient have undertaken to become the preferred commercial partner to our customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin antibiotics,” said Rex Clements, chief executive officer, Centrient. “By broadening of our product portfolio and adding advanced manufacturing capabilities, we will strengthen the delivery of our value proposition of Quality, Reliability and Sustainability. These finished dosage forms are critical medicines in healthcare but face increasing risks of supply shortage.”
 
Dushyant Patel, chairman and managing director, Astral SteriTech, said, “We are proud that with Astral SteriTech’s core competencies and proven strong track record in sterile injectable Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms, we can contribute to synergize and consolidate Centrient’s antibiotics product portfolio, to support their geographical expansion agenda.”